𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Up-regulation of D3 dopamine receptor mRNA by neuroleptics

✍ Scribed by Wei Wang; Kyu-Hee Hahn; John F. Bishop; Da-Qing Gao; Pedro A. Jose; M. Maral Mouradian

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
414 KB
Volume
23
Category
Article
ISSN
0887-4476

No coin nor oath required. For personal study only.

✦ Synopsis

The effects of 14 days neuroleptic treatment on the expression of the D3 dopamine receptor gene was investigated in rats using a sensitive polymerase chain reaction assay. In olfactory tubercle, D3 mRNA levels increased following haloperidol (40%), pimozide (56%), and sulpiride (63%) administration, and in nucleus accumbens, levels increased after haloperidol (50%) and sulpiride (50%). D, expression in the motor striatum did not change with any antagonist tested. Clozapine did not affect D3 expression in any brain region. These data suggest that dopamine antagonists can regulate the expression of the D3 receptor in a brain region selective manner. The findings also suggest

📜 SIMILAR VOLUMES

Regulation of 25-hydroxyvitamin D3-24-hy
Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone
✍ Claudia Zierold; Jamie A. Mings; Hector F. DeLuca 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

## Abstract The 25‐hydroxyvitamin D~3~‐24‐hydroxylase mRNA is tightly and reciprocally regulated by 1,25‐dihydroxyvitamin D~3~ (1,25(OH)~2~D~3~) and parathyroid hormone (PTH). The upregulation of the 24‐hydroxylase by 1,25(OH)~2~D~3~ is well established and occurs at the transcriptional level throu

Antiparkinsonian effects of the novel D3
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors
✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept

Differential modulation of dopamine D1-r
Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390
✍ Jiang Yu; Héctor Coirini; Lillemor Källström; Frits-Axel Wiesel; Allan E. Johnso 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 2 views

Dopamine D 1 -receptor binding in the basal ganglia is differentially regulated by subtype nonspecific dopamine antagonists such as the antipsychotic, Fluphenazine. The purpose of the present study was to determine the relative contributions of D 1 and D 2 receptor systems in the regulation of basal

Up-regulation of estrogen receptor by ta
Up-regulation of estrogen receptor by tamoxifen in human breast cancer
✍ Shinzaburo Noguchi; Kazuyoshi Motomura; Hideo Inaji; Shingi Imaoka; Hiroki Koyam 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 631 KB

Background. Influence of tamoxifen treatment on estrogen receptor (ER) and progesterone receptor (PR) levels in human breast cancer has not been fully elucidated in vivo. This problem was studied in 20 postmenopausal patients with ER-positive and PR-positive primary breast cancer. Each patient unde